Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06977581 · ClinicalTrials.gov registry record · Phase 2

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

A Phase 2 study of Asthma, sponsored by Pfizer.

Recruiting
Registry status
Phase 2
Development phase
252
Enrollment target
20
Study locations

NCT06977581 is a Phase 2 study of Asthma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 252 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06977581, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 2
Development phase
252 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking their regular maintenance treatment(s) for asthma over the last 12 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants will be involved in this study for about 7.5 months. During this time, they will have 9 visits at the study clinic.

Conditions Studied

Asthma

Interventions

  • OTHER Placebo
  • DRUG PF-07275315

Study Locations (20)

California

  • Antelope Valley Clinical Trials - Lancaster
  • NewportNativeMD, Inc. - Newport Beach
  • California Medical Research Associates - Northridge
  • Allergy and Asthma Associates of Santa Clara Valley Research Center - San Jose
  • Allergy & Asthma Clinical Research - Walnut Creek

Illinois

  • Christie Clinic - University - Champaign
  • Innovo Research - Christie Clinic - Champaign
  • Christie Clinic - Windsor - Champaign

Michigan

  • North Ingalls Building - Ann Arbor
  • University of Michigan - Ann Arbor

New Jersey

  • Rutgers, Robert Wood Johnson Medical School - New Brunswick
  • Circuit Clinical / Impact Medical Allergy, Asthma & Immunology - Riverdale

Alabama

  • Velocity Clinical Research, Mobile - Mobile

Arizona

  • Chandler Clinical Trials - Chandler

Colorado

  • Colorado ENT & Allergy - Colorado Springs

Georgia

  • Cpcc-Research Llc - East Point

Trial Details

FieldValue
Enrollment Target 252 participants
Start Date 2025-05-20
Est. Completion 2027-05-31
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06977581

The ClinicalTrials.gov registry entry for NCT06977581 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (84% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06977581 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, Michigan.

Frequently Asked Questions

What is clinical trial NCT06977581 about?

NCT06977581 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of...

What is the current status of trial NCT06977581?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2025-05-20. Estimated completion is 2027-05-31.

What conditions does trial NCT06977581 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT06977581?

The interventions under investigation include: Placebo (OTHER), PF-07275315 (DRUG).

Who is sponsoring clinical trial NCT06977581?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06977581 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.